Interpace Biosciences (IDXG) Misses Q2 EPS by 41c
Tweet
Share
E-mailGet Alerts IDXG Hot Sheet
Join SI Premium – FREE
Interpace Biosciences (OTC: IDXG) reported Q2 EPS of ($0.93), $0.41 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $10.5 million.
For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- TD Cowen Upgrades Flagstar Bank (FLG) to Buy
- TD Cowen Upgrades Flagstar Bank (FLG) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
